Bisoprolol plausible effects on heart rate reduction

Beta-blockers play an important role in heart diseases, mainly in chronic heart failure, hypertension, or ischemic heart disease. However, there is a dispute regarding whether beta-blockers exert their class effect in such diagnoses or if thereare significant differences in efficacy between the agents. 

To help understand the specific differences between beta-blockers and ease the decision-making process of which beta-blocker to administer, we reviewed two studies focused on this topic.

The first study compared the effects of bisoprolol, other β-blockers (carvedilol, metoprolol,nebivolol, atenolol, etc.), and non-β-blocker drugs on long-term cardiovascular events and the risk of mortality in patients with angina pectoris. The study demonstrated a significant long-term reduction in the risk of mortality and various cardiovascular events with bisoprolol compared to other β-blockers and non-β-blocker drugs (see fig1). In summary, the study findings strongly support bisoprolol as the preferred choice for initial treatment of angina in primarycare. (

Fig.1-taken from: Sabidó, M., Thilo, H. and Guido, G., 2019. Long-term effectivenessof bisoprolol in patients with angina: a real-world evidence study.Pharmacological Research, 139, pp.106-112. Kaplan―Meier survival curves for14-year mortality.

The second study aimed to investigate the long-term effects of bisoprolol compared to metoprolol CR/ZOK in controlling blood pressure (BP) and mean dynamic heart rate (HR) in patients with mild-to-moderate primary hypertension over a period of 12 weeks. At the end of the study, during the last 4 hours of the 12-week treatment period, patients' BP and HR were measured. 

Both bisoprolol and metoprolol CR/ZOK were equally effective in managing BP. However, bisoprolol demonstrated a significant decrease in HR (see fig.2). High heart rate is an independent predictive factor for cardiovascular morbidity or fatal events, including those associated with hypertension. Therefore, patients taking bisoprolol have a reduced probability of experiencing such events. (

Fig. 2 Changes in the mean heart rate andthe mean dynamic diastolic blood pressure (DBP) in the last 4 h of thetreatment period from baseline (intent-to-treat population (ITT)). (a) Changein the mean heart rate in the last 4 h of the treatment period from baseline.(b) Change in the DBP in the last 4 h of the treatment period from baseline.Taken from: Yang T. et al. 2017

To summarize the topic, bisoprolol stands out as an effective choice among β-blockers. It has demonstrated significant benefits in long-term usage for angina pectoris, including a reduction in the risk of mortality and various cardiovascular events compared to other β-blockers and non-β-blocker drugs. Additionally, in patients with hypertension, bisoprolol has shown successful results in lowering heart rate, which is crucial in reducing the likelihood of cardiovascular morbidity or fatal events.

More Posts

You Might Also Like